The lawsuit alleges that PROCEPT BioRobotics utilized an undisclosed discount program to incentivize bulk orders, which artificially inflated reported sales and revenue. By encouraging customers to purchase handpiece units beyond actual procedure demand, the company allegedly created a surplus of over 10,000 excess units in field inventory by the end of the class period. These actions, the complaint claims, rendered the company's financial guidance for 2025 unattainable and lacked a factual basis.
Investors Face September Deadline in PROCEPT BioRobotics Securities Suit
Investors who purchased PROCEPT BioRobotics Corporation common stock between February 28, 2024, and February 25, 2026, face a September 22, 2026, deadline to seek lead plaintiff status in an ongoing securities fraud lawsuit, according to the Rosen Law Firm, which is currently representing shareholders in the litigation.
Shareholders who suffered losses exceeding $100,000 may move the court to serve as a lead plaintiff. While no class has been certified yet, affected investors have until the September 22 deadline to act. Those interested in the litigation can contact Phillip Kim at the Rosen Law Firm for further details regarding the contingency fee arrangement and the legal requirements for participation.
Comments (0)
No comments yet. Be the first!